The stock of ProPhase Labs Inc (NASDAQ: PRPH) has decreased by -6.34 when compared to last closing price of 0.36.Despite this, the company has seen a loss of -4.82% in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC bought a new stake in shares of ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 52,394 shares of the company’s stock, valued at approximately $40,000. Squarepoint Ops LLC owned about 0.22% of ProPhase Labs as of its most recent filing with the SEC. A number of other large investors have also recently bought and sold shares of the stock. Warberg Asset Management LLC purchased a new position in shares of ProPhase Labs during the 4th quarter worth $77,000. Renaissance Technologies LLC lifted its stake in shares of ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after purchasing an additional 71,375 shares during the period. Perritt Capital Management Inc lifted its stake in shares of ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after purchasing an additional 107,068 shares during the period. Geode Capital Management LLC lifted its stake in shares of ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after purchasing an additional 42,793 shares during the period. Finally, HighTower Advisors LLC lifted its stake in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares during the period. Institutional investors and hedge funds own 9.45% of the company’s stock. ProPhase Labs Trading Down 1.9% Shares of ProPhase Labs stock opened at $0.35 on Wednesday. ProPhase Labs, Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $4.84. The firm has a market cap of $14.54 million, a PE ratio of -0.28 and a beta of -0.43. The business’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.46. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its quarterly earnings results on Tuesday, May 20th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.06. ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%. The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $2.45 million. Analysts anticipate that ProPhase Labs, Inc. will post -1.27 earnings per share for the current year. Analysts Set New Price Targets Separately, Wall Street Zen assumed coverage on ProPhase Labs in a research note on Tuesday, February 25th. They set a “sell” rating on the stock. Get Our Latest Analysis on PRPH ProPhase Labs Company Profile (Free Report) ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. See Also Five stocks we like better than ProPhase Labs Low PE Growth Stocks: Unlocking Investment Opportunities AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway How Investors Can Find the Best Cheap Dividend Stocks Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Stocks to Consider Buying in October Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding PRPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report).
Is It Worth Investing in ProPhase Labs Inc (NASDAQ: PRPH) Right Now?
PRPH has 36-month beta value of -0.44. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PRPH is 36.67M, and currently, short sellers hold a 0.88% ratio of that float. The average trading volume of PRPH on June 13, 2025 was 1.86M shares.
PRPH’s Market Performance
PRPH’s stock has seen a -4.82% decrease for the week, with a 0.00% drop in the past month and a -20.13% fall in the past quarter. The volatility ratio for the week is 4.22%, and the volatility levels for the past 30 days are at 7.00% for ProPhase Labs Inc The simple moving average for the past 20 days is -3.58% for PRPH’s stock, with a -65.34% simple moving average for the past 200 days.
Analysts’ Opinion of PRPH
Many brokerage firms have already submitted their reports for PRPH stocks, with H.C. Wainwright repeating the rating for PRPH by listing it as a “Buy.” The predicted price for PRPH in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on December 20, 2021 of the previous year 2021.
Dawson James gave a rating of “Buy” to PRPH, setting the target price at $25 in the report published on January 20th of the previous year.
PRPH Trading at 3.16% from the 50-Day Moving Average
After a stumble in the market that brought PRPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.97% of loss for the given period.
Stock Fundamentals for PRPH
Current profitability levels for the company are sitting at:
- -5.71 for the present operating margin
- -0.02 for the gross margin
The net margin for ProPhase Labs Inc stands at -7.88. The total capital return value is set at -1.24. Equity return is now at value -58.71, with -30.25 for asset returns.
Based on ProPhase Labs Inc (PRPH), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at 3.34. The interest coverage ratio of the stock is -11.53.
Currently, EBITDA for the company is -32.34 million with net debt to EBITDA at -0.74. When we switch over and look at the enterprise to sales, we see a ratio of 5.62. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To put it simply, ProPhase Labs Inc (PRPH) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
